Keros Therapeutics (NASDAQ:KROS) Now Covered by Analysts at Scotiabank

Scotiabank started coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research report released on Wednesday morning, MarketBeat Ratings reports. The firm issued a sector outperform rating and a $77.00 target price on the stock.

A number of other brokerages also recently issued reports on KROS. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer started coverage on Keros Therapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target for the company. Truist Financial reiterated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Finally, Bank of America reduced their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $89.11.

Keros Therapeutics Stock Performance

Shares of KROS opened at $62.18 on Wednesday. The business’s 50-day moving average is $52.79 and its two-hundred day moving average is $52.08. The company has a market capitalization of $2.24 billion, a P/E ratio of -12.07 and a beta of 1.23. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The company had revenue of $0.04 million during the quarter. During the same quarter last year, the firm earned ($1.27) EPS. Analysts forecast that Keros Therapeutics will post -4.88 EPS for the current year.

Insider Transactions at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KROS. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics in the 2nd quarter valued at $128,000. Ameritas Investment Partners Inc. increased its holdings in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the last quarter. Quest Partners LLC raised its position in Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after purchasing an additional 4,789 shares during the period. XTX Topco Ltd acquired a new position in Keros Therapeutics during the second quarter worth $228,000. Finally, Bayesian Capital Management LP acquired a new position in Keros Therapeutics during the first quarter worth $267,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.